|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
104,690,000 |
Market
Cap: |
100.76(B) |
Last
Volume: |
461,806 |
Avg
Vol: |
778,943 |
52
Week Range: |
$692.45 - $993.35 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 150 |
Guru Rank Value : 6.9 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
63,057 |
86,630 |
125,378 |
345,405 |
Total Sell Value |
$59,114,723 |
$78,626,388 |
$110,854,479 |
$264,225,777 |
Total People Sold |
12 |
13 |
15 |
19 |
Total Sell Transactions |
25 |
38 |
56 |
131 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Murphy Andrew J |
EVP Research |
|
2024-03-14 |
4 |
AS |
$951.92 |
$5,531,290 |
D/D |
(5,783) |
48,306 |
|
1% |
|
Murphy Andrew J |
EVP Research |
|
2024-03-13 |
4 |
D |
$971.82 |
$13,816,365 |
D/D |
(14,217) |
54,089 |
|
- |
|
Murphy Andrew J |
EVP Research |
|
2024-03-13 |
4 |
OE |
$399.66 |
$7,993,200 |
D/D |
20,000 |
68,306 |
|
- |
|
Mccourt Marion |
EVP Commercial |
|
2024-03-01 |
4 |
AS |
$967.50 |
$346,365 |
D/D |
(358) |
13,431 |
|
-2% |
|
Ryan Arthur F |
Director |
|
2024-03-01 |
4 |
AS |
$967.50 |
$98,205 |
D/D |
(100) |
18,282 |
|
-2% |
|
Sing George L |
Director |
|
2024-02-26 |
4 |
S |
$990.00 |
$992,500 |
D/D |
(1,000) |
26,349 |
|
2% |
|
Sing George L |
Director |
|
2024-02-26 |
4 |
OE |
$413.33 |
$413,330 |
D/D |
1,000 |
26,849 |
|
- |
|
Stahl Neil |
EVP Research and Development |
|
2024-02-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,020 |
50,999 |
|
- |
|
Larosa Joseph J |
EVP General Counsel and Secret |
|
2024-02-26 |
4 |
S |
$990.00 |
$990,000 |
D/D |
(1,000) |
36,543 |
|
2% |
|
Bassler Bonnie L |
Director |
|
2024-02-26 |
4 |
S |
$979.25 |
$836,280 |
D/D |
(854) |
1,382 |
|
2% |
|
Bassler Bonnie L |
Director |
|
2024-02-26 |
4 |
OE |
$391.92 |
$334,700 |
D/D |
854 |
2,236 |
|
- |
|
Sing George L |
Director |
|
2024-02-23 |
4 |
S |
$985.00 |
$492,500 |
D/D |
(500) |
26,349 |
|
2% |
|
Sing George L |
Director |
|
2024-02-23 |
4 |
OE |
$413.33 |
$206,665 |
D/D |
500 |
26,849 |
|
- |
|
Sing George L |
Director |
|
2024-02-22 |
4 |
S |
$960.00 |
$2,895,000 |
D/D |
(3,000) |
26,349 |
|
-0% |
|
Sing George L |
Director |
|
2024-02-22 |
4 |
OE |
$413.33 |
$1,239,990 |
D/D |
3,000 |
27,349 |
|
- |
|
Larosa Joseph J |
EVP General Counsel and Secret |
|
2024-02-22 |
4 |
S |
$967.65 |
$967,650 |
D/D |
(1,000) |
37,543 |
|
-0% |
|
Yancopoulos George |
Bd. Co-Chair, President & CSO |
|
2024-02-15 |
4 |
D |
$953.83 |
$117,894,342 |
D/D |
(123,601) |
801,608 |
|
- |
|
Yancopoulos George |
Bd. Co-Chair, President & CSO |
|
2024-02-15 |
4 |
OE |
$399.66 |
$69,030,474 |
D/D |
172,723 |
925,209 |
|
- |
|
Van Plew Daniel P |
EVP & General Mgr, Industrial |
|
2024-02-14 |
4 |
S |
$937.94 |
$9,831,727 |
D/D |
(10,434) |
20,378 |
|
-2% |
|
Van Plew Daniel P |
EVP & General Mgr, Industrial |
|
2024-02-09 |
4 |
D |
$951.68 |
$23,735,851 |
D/D |
(24,941) |
30,812 |
|
- |
|
Van Plew Daniel P |
EVP & General Mgr, Industrial |
|
2024-02-09 |
4 |
OE |
$372.46 |
$13,382,510 |
D/D |
35,375 |
47,153 |
|
- |
|
Fenimore Christopher R. |
SVP Finance & CFO |
|
2024-02-09 |
4 |
S |
$950.49 |
$4,689,320 |
D/D |
(4,919) |
14,372 |
|
-1% |
|
Sing George L |
Director |
|
2024-02-09 |
4 |
S |
$955.00 |
$477,500 |
D/D |
(500) |
26,349 |
|
-1% |
|
Sing George L |
Director |
|
2024-02-09 |
4 |
OE |
$413.33 |
$206,665 |
D/D |
500 |
26,849 |
|
- |
|
Sing George L |
Director |
|
2024-02-08 |
4 |
S |
$945.00 |
$472,500 |
D/D |
(500) |
26,349 |
|
-2% |
|
1366 Records found
|
|
Page 1 of 55 |
|
|